Health experts presented findings showing the drugs helped severely obese youngsters shed pounds on top of the diet and ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth. Check out why I ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

New data shows that more patients with type 2 diabetes achieved an average blood sugar level below 7% after using Novo Nordisk’s Victoza (liraglutide) for the first time, at any given time point ...